PulmoBioTech Inc (PulmoBioTech), a diagnostic imaging company, announced the appointment of Professor John Wallwork to the board of the company as non-executive chairman. Wallwork will also be chairing the company’s Scientific Advisory Board where his knowledge and background in Pulmonary Hypertension as well as his experience in the management of R&D will be of great benefit.

Commenting on the appointment, Garry McCann, chief executive officer Pulmo BioTech said “we are delighted that Professor Wallwork has agreed to join the board of Pulmo BioTech. The Professor’s depth of experience and knowledge will be of great benefit to the company as we move towards Phase II Human Trials for our PulmoBind product candidate for the Molecular Imaging of the vascular system of the lungs”

Biographical Details


Professor John Wallwork is currently Professor of Cardiothoracic Surgery and director of research & development at Papworth Hospital NHS Foundation Trust, Cambridge.

Before being appointed as a Consultant at Papworth Hospital in 1981, he was chief resident at Stanford University Hospital in California for nearly 2 years, where he first became involved in heart and heart-lung transplantation and has played a major role in the development of heart-lung transplantation at Papworth Hospital.

He performed Europe’s first successful heart-lung transplant in 1984 and, with Professor Sir Roy Calne, the world’s first heart-lung and liver transplant in 1986. During this period he and his colleague, Professor Tim Higenbottam, were the first to introduce the use of long-term Prostacycline for Primary Pulmonary Hypertension.

He was director of the Transplant Service from 1989 to 2006, chaired the UK Transplant Cardiothoracic Advisory Group from 1994 to 2006 and was Medical Director of Papworth Hospital from 1997 to 2002. On 1st October 2002 the University of Cambridge awarded him an honorary Chair in Cardiothoracic Surgery.